Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

10.78
-0.2500-2.27%
Post-market: 10.780.00000.00%19:30 EDT
Volume:217.08K
Turnover:2.37M
Market Cap:213.74M
PE:-3.47
High:11.12
Open:11.12
Low:10.72
Close:11.03
52wk High:22.55
52wk Low:9.69
Shares:19.83M
Float Shares:18.25M
Volume Ratio:1.10
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1046
EPS(LYR):2.30
ROE:-17.16%
ROA:-11.78%
PB:0.81
PE(LYR):4.69

Loading ...

Keros Therapeutics Inc Files Initial Beneficial Ownership Statement for Director Charles W. Newton

Reuters
·
Mar 12

Keros Therapeutics Director Jean Jacques Bienaime Acquires Common Shares

Reuters
·
Mar 12

Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks

TIPRANKS
·
Mar 11

Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL)

TIPRANKS
·
Mar 10

Keros Therapeutics, Massachusetts Hospital Partner to Design Trial for Potential Lou Gehrig's Disease Treatment

MT Newswires Live
·
Mar 09

Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center

TIPRANKS
·
Mar 09

Keros Therapeutics presents additional data from Phase 1 of rinvatercept

TIPRANKS
·
Mar 09

Keros Therapeutics Announces Collaboration With Sean M. Healey & Amg Center for ALS

THOMSON REUTERS
·
Mar 09

Keros Therapeutics (KROS) Receives a Buy from Leerink Partners

TIPRANKS
·
Mar 06

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility

TIPRANKS
·
Mar 06

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Keros Therapeutics (KROS) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Mar 05

Keros Highlights Rinvatercept Strategy in Updated Investor Presentation

TIPRANKS
·
Mar 05

Keros Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 05

Keros (KROS) posts FY 2025 net income of USD 87.0 million

Reuters
·
Mar 05

Keros Therapeutics Q4 Net Income USD -23.461 Million

THOMSON REUTERS
·
Mar 05

Keros Therapeutics Adds Veteran Finance Leader to Board

TIPRANKS
·
Feb 27

Keros Therapeutics names Charles Newton to board as Carl Gordon steps down

Reuters
·
Feb 27

Keros Therapeutics Appoints Charles Newton to Its Board of Directors

THOMSON REUTERS
·
Feb 27

Press Release: Keros Therapeutics Appoints Charles Newton to its Board of Directors

Dow Jones
·
Feb 27